Taiwan Expands Cancer Coverage Under National Health Insurance Scheme
Taiwan’s National Health Insurance (NHI) is set to expand its coverage to include three types of cancer immunotherapies starting June 1, 2025. The new scheme will cover first-line treatments for non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and early stages of triple-negative breast cancer (TNBC).
The decision, which will involve an annual allocation of NT$3.295 billion ($101.28 million) from a dedicated cancer fund, is expected to benefit between 2,700 and 3,400 patients. NSCLC patients will be the biggest beneficiaries, followed by those with TNBC and metastatic colorectal cancer.
According to Huang Yu-wen, director of Taiwan’s Medical Review and Pharmaceutical Benefits Division, cancer patients can expect to save approximately NT$1.71 million ($52,564) to NT$2.47 million annually in medical expenses. The inclusion of pembrolizumab and atezolizumab in the NHI system follows discussions with local medical communities and patient groups, aligning with international treatment guidelines set by the United States National Comprehensive Cancer Network (NCCN).
The expansion of cancer coverage under Taiwan’s NHI demonstrates the country’s commitment to improving healthcare outcomes for its citizens, particularly those battling cancer. By reducing the financial burden of cancer treatment, the NHI aims to ensure that patients receive the necessary care without facing significant out-of-pocket expenses.
